1 Min Read
April 25 (Reuters) - AveXis Inc:
* AVEXIS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 TRIAL OF AVXS-101 IN PRE-SYMPTOMATIC SMA TYPES 1, 2 AND 3 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.